WOMED
Womed, the women's health company pioneering innovative, safe and effective treatments to free women from uterine pathologies, today announced that the results of the PREG2 clinical trial demonstrated Womed Leaf® is effective in the management of severe and moderate intrauterine adhesions (IUAs), the primary mechanical cause for female infertility. No device indicated for IUA prevention has been shown to be effective in this specific patient group. The PREG2 trial results were presented today by Prof. Jean-Louis Benifla, head of the ObGyn department at Lariboisière Hospital – APHP, Paris, France, during the Choix des Armes conference in Marseille, France.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240307289661/en/
Womed Leaf mode of action
IUA, which refers to the pathological binding of the uterine walls, is caused by poor scarring of the uterus after procedures such as dilation and curettage or fibroid removal, and can occur in 20% to 45% of those procedures. IUAs are a major cause of infertility, recurrent miscarriages and pain. IUA treatment, called adhesiolysis, consists of surgically cutting the adhesion, but the very high recurrence rate leaves women unsure and anxious about their chance to conceive.
Womed Leaf® is the first and only mechanical barrier to protect against IUA. It is composed of a soft film made from Womed's proprietary polymer, which is inserted like an IUD at the end of the uterine procedure, expands into the entire cavity to prevent the direct contact of the uterine walls against each other for a week, and is naturally discharged afterwards.
PREG2 is an international, randomized clinical trial designed to measure Womed Leaf's effectiveness. 160 women with severe or moderate IUA were randomly assigned to receive a Womed Leaf or not after adhesiolysis surgery. At the six week follow up visit, women who received Womed Leaf were 2.4 times more likely to have no adhesion than those in the control group. All other efficacy endpoints were also statistically favorable to Womed Leaf. From a safety perspective, there were no serious adverse events and no device related adverse events. Post-operative pain and discomfort from vaginal discharge were low and equally reported by patients in both groups. The details of the PREG2 trial will soon be published in a peer-reviewed journal.
"The results of this landmark study, rigorously conducted in several hospitals around the world, are great news for our patients," said Prof. Herve Fernandez, Bicetre University Hospital – APHP, Paris, France and principal investigator of the study. "Womed Leaf, which protects the cavity during the healing phase, is breaking new ground and becomes, to the best of our knowledge, the first technology to achieve a proof of efficacy in this highly complex population."
"Womed has achieved an unprecedented feat and we are very proud to be the first team to offer a solution to women with scarred uterus in their exhausting journey to become pregnant," said Gonzague Issenmann, co-founder and CEO of Womed. "Womed Leaf, which is already registered in Europe and Brazil, will be marketed through commercial partners."
About PREG2
PREG2 is a multi-center, double-blind, randomized, controlled, stratified, two-arm superiority clinical trial conducted in 16 centers in 7 countries. 160 patients scheduled for hysteroscopic adhesiolysis because of symptomatic severe or moderate IUA were randomized after surgery to either have a Womed Leaf film inserted (treatment group) or not (control group). The reduction in IUA severity at six week follow up was significantly higher in the treatment compared to the control group (mean AFS score reduction 5.2 ± 2.8 vs. 4.2 ± 3.2; p=0.0153). Similarly, the responder rate was significantly higher in the treatment arm compared to controls (51% vs 29% OR 2.72 [CI 1.353 - 5.447]; p=0.0052). The absence of adhesions at follow up was significantly higher in the treatment group (41% vs 24% OR 2.44 [CI 1.161 - 5.116]; p=0.0189). None of the reported adverse events were considered related to the device. Post operative pain and discomfort from vaginal discharge was equivalent in both groups (17% vs 27% and 10% vs 10% respectively, in the treatment and control groups).
About WOMED
Womed was founded by health tech entrepreneur Gonzague Issenmann, biomedical polymer specialist Prof. Xavier Garric and reproductive specialist Dr. Stephanie Huberlant, to commercialize an invention from Garric's Polymers for Health and Biomaterials lab at the University of Montpellier, France. Womed's proprietary degradable polymer technology is designed specifically for temporary uterine implantation and controlled drug delivery.
The first product, Womed Leaf®, is a medical device to treat and prevent bonding of the uterine walls, which occurs in particular in one in five women treated for miscarriage. Womed's pipeline of intrauterine drug delivery products include treatments for fibroids, endometriosis and acute uterine bleeding.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240307289661/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera1.6.2025 14:00:00 CEST | Press release
Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpointAll key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomesNo serious adverse events considered related to rusfertide were reportedRusfertide has received Orphan Drug designation and Fast Track designation from the U.S. FDA Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary e
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 14:00:00 CEST | Press release
BRUKINSA plus venetoclax demonstrated high response rates and a favorable safety profile across CLL patient types in SEQUOIA Arm D, including those with high-risk del(17p) mutational statusAt 5-year follow-up of SEQUOIA Arm C, BRUKINSA monotherapy showed sustained OS and PFS benefit in hard-to-treat del(17p) CLL patients versus historical data BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall dee
Andersen Consulting tilføjer Stratence Partners30.5.2025 16:07:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform med en samarbejdsaftale med Stratence Partners, der er et konsulentfirma med base i Storbritannien, som hjælper globale virksomheder med at øge markedsandele og forbedre rentabiliteten gennem deres ekspertise inden for prisfastsættelse, strategisk optimering, kommerciel effektivitet og digital transformation. Stratence Partners har en resultatorienteret tilgang og er forpligtet på bæredygtig forandring, hvorved de hjælper deres kunder gennem en unik kombination af konsulentbistand, midlertidige ledelsesindsater og oplæringskurser samt deres egne metoder og løsninger inden for datastyring, datavidenskab (AI), værktøjer og systemer. "Samarbejdet med Andersen Consulting er et spændende skridt for vores firma," sagde Fernando Ventureira, administrerende direktør for Stratence Partners. "I vores arbejde med hos ledere over hele verden har vi erfaret, at deres behov rækker ud over strategisk prisfastsættelse og driftsoptimering. Vores kunder værdsætte
You Up? Grindr’s “Right Now” Goes Global30.5.2025 15:00:00 CEST | Press release
More places, more people – Grindr’s real-time hookup feature makes connecting faster than ever Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 14:00:00 CEST | Press release
Only approximately 2 out of 10 people in the US and 3 out of 10 people in Europe with certain rare, advanced blood cancers receive access to CAR T-cell therapy1,2,3New roadmap report aims to inspire collective action of stakeholder groups and invites additional CAR T-cell therapy leaders to join the coalition Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative fin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom